Medtronic plcMDT recently announced FDA approval for its MiniMed 670G system for patients with type 1 diabetes between seven and 13 years of age. Notably, the approval was based on positive data from ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Editor’s Note: A few weeks ago, a Type 1 diabetes patient authored a blog post about why she didn’t want to switch to Medtronic’s MiniMed 670G billed as the industry’s first hybrid closed-loop insulin ...

Aggregated real-world outcome data collected from thousands of Medtronic MiniMed 670G users indicate that patients on the system spend an average 71% of their time within an optimal glycemic range.

Medtronic plcMDT announced that the FDA has approved a new arm indication for the Guardian Sensor 3 continuous glucose monitor (CGM) used with the MiniMed 670G insulin pump. Notably, the Guardian ...

Medtronic plc, the global leader in medical technology, announced that the US Food and Drug Administration (FDA) has approved the use of the MiniMed 670G system in patients with type 1 diabetes seven ...

Medtronic says real-world data show its MiniMed 670G glucose management system increased time in range for people with diabetes. Medtronic has announced clinical outcomes for the MiniMed 670G system, ...

Results show how the hybrid closed loop system reduced glycemic variability, which leads to fewer long-term complications from type 1 disease. The trial reports what had been announced already: the ...

On September 28, 2016, the US Food and Drug Administration (or FDA) approved Medtronic’s (MDT) MiniMed 670G system as the first hybrid closed-loop system that partially automates the continuous ...